accomplished to date
✔ 2024 we were awarded a prize for innovation in a TV contest based on the Shark Tank show.
✔ 2023, The Israel Innovation Authority (IIA) chose us to participate in the Singapore-Israeli delegation.
✔ 2022, We passed the scrutinization of Josseph Sassoon Group for future potential investment.
✔ 2021, Won a contest by Vision-Elements (AI).
position
✔ Clinical trial with over 450 lesions, and more than 10,000 measurements.
✔ Regulatory strategy. GSAP.
✔ Patent, at a national stage (After PCT and IDS).
✔ New PatScope Scanner (MVP, trl6).
✔ Business plan. Business model.
✔ Conference presentations.
✔ Proposal to Space Agency to investigate astronaut's skin degradation under microgravity conditions.
market
-
Clinics and centers, Dermatologists, General practitioners (GPs), Beauticians, and home users.
-
The TAM is greater than $1 billion USD, and growing rapidly with a CAGR > 10%.
- We have attracted and are increasingly continuing to attract Clinics, worldwide.
-
business model
-
Sales - of the scanner as standalone unit and as adapter for smartphones.
-
AI - for lesion distortion as decision support.
-
Telemedicine - our dermatologists will assist with follow-ups.
-
Reimbursement - following CPT code similar to x-ray, CT, and MRI.
current activities
• We are in preliminary planning for the development of the next generation of the PatScope.
• Submitting a pre-submission to the FDA to confirm the regulatory pathway we built with Duet Medical and GSAP as control and re-examination. Design clinical trials according to the FDA's answer to the Pre-Sub. Exception of Brand Designation.
• Market survey to better define the scanner's positioning.
• Expansion of experiments in hospitals.
• Development and production portfolio with regulatory affairs.
• DLLD: Modifying parameters for Deep Learning for Lesion Distortion (DLLD).